Overview

Fexofenadine Study On Filipino Children for The Relief of Perennial And Intermittent Allergic Rhinitis

Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
0
Participant gender:
All
Summary
To determine the safety and efficacy of Fexofenadine (Telfast®) 30mg pediatric tablets on Filipino children aged 6 to 11 for the relief of symptoms associated with perennial and intermittent allergic rhinitis.
Phase:
Phase 4
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
Sanofi
Treatments:
Fexofenadine
Terfenadine
Criteria
Inclusion Criteria:

- Children who manifest allergic rhinitis symptoms such as sneezing, rhinorrhea, itchy
nose/palate/throat and/or itchy/watery/red eyes.